

Arne Kristian Skulberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3226367/publications.pdf>

Version: 2024-02-01

15
papers

141
citations

1307594

7
h-index

1199594

12
g-index

19
all docs

19
docs citations

19
times ranked

111
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-blind, randomised, controlled trial. <i>Addiction</i> , 2022, 117, 1658-1667.	3.3	9
2	Naloxone administration—no balance without titration. <i>Addiction</i> , 2022, 117, 2750-2751.	3.3	1
3	Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial. <i>PLoS ONE</i> , 2022, 17, e0268822.	2.5	1
4	Intranasal Naloxone Administration. <i>New England Journal of Medicine</i> , 2021, 384, e96.	27.0	1
5	REBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trial. <i>Trials</i> , 2021, 22, 511.	1.6	22
6	The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanyl in human volunteers. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1901-1908.	1.9	5
7	Prehospital naloxone administration—what influences choice of dose and route of administration?. <i>BMC Emergency Medicine</i> , 2020, 20, 71.	1.9	10
8	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. <i>BMJ Open</i> , 2020, 10, e041556.	1.9	1
9	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. <i>BMJ Open</i> , 2020, 10, e041556.	1.9	1
10	Ambulance-Attended Opioid Overdoses: An Examination into Overdose Locations and the Role of a Safe Injection Facility. <i>Substance Abuse</i> , 2019, 40, 383-388.	2.3	13
11	Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. <i>Addiction</i> , 2019, 114, 859-867.	3.3	15
12	Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 873-883.	1.9	16
13	Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanyl. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1547-1553.	1.9	8
14	Pharmacokinetics of a new, nasal formulation of naloxone. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 555-562.	1.9	31
15	Opioid education programs and nasal naloxone rescue kits in Europe. <i>Toxicology Letters</i> , 2017, 280, S43.	0.8	0